Home Neoplasma 2018 Neoplasma Vol.65, No.5, p.815-821, 2018

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.65, No.5, p.815-821, 2018

Title: TMEM45B is a novel predictive biomarker for prostate cancer progression and metastasis
Author: F. Luo, K. Yang, Y. Z. Wang, D. Lin

Abstract: It is urgently required to explore the clinical relevance of TMEM45B expression and Prostate cancer (PCa), and determine the predictive significance of TMEM45B as a biomarker for PCa patients. Patient-derived xenograft (PDX) models were developed for PCa with different metastatic potential (LTL-418, LTL-313B, LTL-313H and LTL-331). The gene expression microarray of LTL-313H and LTL-313B which derived from a single PCa patient was performed to identify the candidate biomarker gene, TMRM45B. MSKCC and TCGA PCa patient cohorts were introduced to analyze the clinical significance of TMEM45B expression. Quantitative Real-Time PCR (qRT-PCR) revealed that there was a significant increase of TMEM45B expression in the LTL-313H and LTL-331 high metastatic potential tumor lines compared to the LTL-418, LTL-313B low metastatic potential tumor lines. In the MSKCC PCa cohort, the mRNA level of TMEM45B in patients with metastasis was significantly higher than that in primary PCa (P=0.001) and benign prostate hyperplasia patients (BPH) (Pstablished in high-level TMEM45B patients compared to those with low levels (P=0.007). The combined results indicate that increased TMEM45B expression appears significantly associated with prostate carcinoma progression and metastasis, and this provides a new prognostic biomarker for predicting metastatic potential in PCa patients; especially those with primary PCa.

Keywords: TMEM45B, Prognosis, Biomarker, Prostate Cancer, Metastasis, Patient-derived xenograft
Published online: 24-Sep-2018
Year: 2018, Volume: 65, Issue: 5 Page From: 815, Page To: 821
doi:10.4149/neo_2018_170822N551
Price: 14.70 €






© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.